Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • September 30, 2026

Share

Original Source(s)

Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

  • September 30, 2026

Related Content

Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies

Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors: A Secondary

A Glimpse into the Future of Analytical Instrument Design?

Michael John Fanous’s portable scanner uses AI to reconstruct images blurred by continuous high-speed acquisition